Market Overview

UPDATE: Aegis Capital Initiated Ironwood Pharmaceuticals with Buy, $17 PT; Unique Gastrointestinal Opportunity

Related IRWD
Ironwood Presents IW-9179 Phase IIa Data At American College Of Gastroenterology 2014 Annual Scientific Meeting
Ironwood Pharmaceuticals Announces Initiation Of Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation
Related IRWD
Markets Open Higher; VeriFone Profit Tops Street View
Benzinga's Top Downgrades

In a recently released report, Aegis Capital said it initiated coverage on Ironwood Pharmaceuticals (NASDAQ: IRWD) with a Buy rating and a $17 price target on shares.

Aegis Capital commented, "The current market for chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C) is substantial, with over 100mm people estimated to suffer from these disorders in the U.S., Europe, and Japan. Roughly 8mm individuals in the U.S. alone seek treatment for constipation-related disorders every year. Existing therapies are either only palliative or marginally effective, with substantial side effect risk. We believe this creates a compelling opportunity for firms like Ironwood, since linaclotide is based on a naturally-occurring hormone called uroguanylin and utilizes an evolutionarily-derived mechanism of action."

Ironwood Pharmaceuticals closed at $13.87 on Friday.

Latest Ratings for IRWD

DateFirmActionFromTo
Nov 2014Cantor FitzgeraldDowngradesHoldSell
Sep 2014Cowen & CompanyDowngradesOutperformMarket Perform
Aug 2014Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (IRWD)

Around the Web, We're Loving...

Get Benzinga's Newsletters